Details

Autor(en) / Beteiligte

• Mettler, Camille
• Petit, Cassandre
• Ernest, Vincent
• Asli, Bouchra
• Daniel, Marie-Thérèse
• Mathis, Stéphanie
• Zini, Jean Marc
• Faucher, Benoit
• Ebbo, Mikael
• Legendre, Paul
• Malphettes, Marion

Titel

Erythroblastic synartesis associated with lymphoproliferative disorder: There can be more than meets the eye

Ist Teil von

• Clinical immunology (Orlando, Fla.), 2022-03, Vol.236, p.108951-108951, Article 108951

Ort / Verlag

United States: Elsevier Inc

Erscheinungsjahr

2022

Link zum Volltext

Quelle

MEDLINE

Beschreibungen/Notizen

• Erythroblastic synartesis is a rare cause of acquired dyserythropoiesis. Only 9 cases have been previously reported. We hereby report 3 cases of patients diagnosed with erythroblastic synartesis associated with monoclonal immunoglobulin and an overt malignant lymphoid disorder. A different B-cell clone may produce the monoclonal immunoglobulin, forming a biclonal disorder. In light of these data and literature review, treatment targeting the paraprotein seems to be efficient to control synartesis and correct anemia. In the case of monoclonal gammapathy associated with chronic lymphocytic leukemia, therapeutics should be adapted to control both chronic lymphocytic leukemia and monitored monoclonal immunoglobulin titer. •Erythroblastic synartesis is a rare cause of acquired dyserythropoiesis.•Treatment targeting the paraprotein seems to be efficient to control synartesis and correct anemia.•Paraprotein level monitoring is essential when treating patients with synartesis.